Adaptimmune Therapeutics PLC (NASDAQ:ADAP) – Equities researchers at SunTrust Banks raised their FY2017 earnings estimates for shares of Adaptimmune Therapeutics PLC in a research note issued to investors on Thursday. SunTrust Banks analyst P. Lawson now anticipates that the biotechnology company will post earnings per share of ($0.76) for the year, up from their prior estimate of ($1.12). SunTrust Banks currently has a “Buy” rating and a $10.00 target price on the stock. SunTrust Banks also issued estimates for Adaptimmune Therapeutics PLC’s Q4 2017 earnings at ($0.26) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at $0.33 EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($0.50) EPS, FY2019 earnings at ($1.12) EPS, FY2020 earnings at ($0.95) EPS and FY2021 earnings at ($0.56) EPS.

A number of other research firms also recently issued reports on ADAP. Leerink Swann reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a report on Wednesday, October 4th. TheStreet raised shares of Adaptimmune Therapeutics PLC from a “d” rating to a “c” rating in a report on Thursday, November 2nd. ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $11.58.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-adaptimmune-therapeutics-plc-adap-increased-by-analyst/1684901.html.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at $8.44 on Monday. Adaptimmune Therapeutics PLC has a fifty-two week low of $3.76 and a fifty-two week high of $9.29.

Hedge funds have recently added to or reduced their stakes in the business. Alps Advisors Inc. increased its position in shares of Adaptimmune Therapeutics PLC by 4.9% in the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock valued at $287,000 after acquiring an additional 2,996 shares during the period. Matrix Capital Management Company LP purchased a new position in shares of Adaptimmune Therapeutics PLC during the second quarter valued at about $39,027,000. Point72 Asset Management L.P. purchased a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $2,883,000. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics PLC by 75.4% during the first quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock valued at $4,302,000 after buying an additional 335,700 shares during the period. Finally, Baillie Gifford & Co. increased its position in shares of Adaptimmune Therapeutics PLC by 4.2% during the third quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock valued at $11,297,000 after buying an additional 55,996 shares during the period. Hedge funds and other institutional investors own 68.12% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.